Compare CCB & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | DBVT |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2018 | 2014 |
| Metric | CCB | DBVT |
|---|---|---|
| Price | $82.29 | $19.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $126.67 | $32.04 |
| AVG Volume (30 Days) | 113.2K | ★ 239.2K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 3.06 | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | $96.61 | $35.04 |
| Revenue Next Year | $22.66 | $2,360.78 |
| P/E Ratio | $27.31 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $70.72 | $7.53 |
| 52 Week High | $120.05 | $26.19 |
| Indicator | CCB | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 45.29 |
| Support Level | $73.44 | $18.75 |
| Resistance Level | $85.88 | $23.52 |
| Average True Range (ATR) | 2.21 | 0.95 |
| MACD | 0.32 | -0.15 |
| Stochastic Oscillator | 58.03 | 18.78 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.